ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OCUL Ocular Therapeutix Inc

9.78
0.56 (6.07%)
After Hours
Last Updated: 23:03:34
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ocular Therapeutix Inc NASDAQ:OCUL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.56 6.07% 9.78 9.79 9.90 9.90 9.18 9.22 4,642,584 23:03:34

Ocular Therapeutix™ to Present at September Retina Meetings

05/09/2024 12:30pm

GlobeNewswire Inc.


Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart


From Aug 2024 to Oct 2024

Click Here for more Ocular Therapeutix Charts.

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced multiple presentations across four retina meetings being held in Portugal and Spain in September 2024.

Presentation Details (all times CEST): 

The Retina Society 57th Annual Scientific Meeting: September 11-15, Lisbon, Portugal

  • Oral Presentation: 52-week Rescue-Free Subjects Treated with Axitinib Hydrogel Implant (OTX-TKI) in the US Phase 1 Clinical Trial for Neovascular Age-Related Macular DegenerationSession: Age Related Macular Degeneration IIIPresentation Date/Time: Friday, September 13, 8:48 AM – 8:55 AMPresenter: Andrew A. Moshfeghi, MD, MBA
  • Oral Presentation: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial (Late Breaking Presentation)Session: Diabetic Retinopathy IIPresentation Date/Time: Saturday, September 14, 2024, 12:39 PM – 12:46 PMPresenter: Dennis M. Marcus, MD

Ophthalmology Futures Forums (OFF) Retina Forum 2024: September 18, Barcelona, Spain

  • Panel Title: Tyrosine Kinase Inhibitors and Other Novel Mechanisms for the Treatment of Neovascular AMD: Is There Unmet Need?Session: Panel 1Panel Date/Time: Wednesday, September 18, 10:00 AM – 10:30 AMOcular Therapeutix Panelist: Nadia K. Waheed, MD, MPH, Chief Medical Officer
  • Panel Title: The Impact of Extended Duration with Injections on Novel Drug Delivery Approaches for Posterior Segment DiseasesSession: Panel 2Panel Date/Time: Wednesday, September 18, 10:30 AM – 11:00 AMOcular Therapeutix Panelist: Peter K. Kaiser, MD, Chief Development Officer
  • Company Presentation: Ocular Therapeutix: Transformation into a Retina-focused CompanySession: Company Presentations 2Session Date/Time: Wednesday, September 18, 4:00 PM – 4:40 PMPresenter: Peter K. Kaiser, MD, Chief Development Officer

EURETINA Innovation Spotlight (EIS): September 18, Barcelona, Spain

  • Company Presentation: Changing the Future Paradigm for the Management of Retinal Vascular DiseasesSession: VEGF Related and Other Retinal Indications (Session 2)Presentation Date/Time: Wednesday, September 18, 2:05 PM – 2:10 PMPresenter: Nadia K. Waheed, MD, MPH, Chief Medical Officer

24th EURETINA Congress (EURETINA 2024): September 19-22, Barcelona, Spain

  • Oral Presentation: 48-Week Safety and Efficacy Results from the Phase 1 HELIOS trial of Sustained-Release Axitinib Implant (OTX-TKI) for Non-Proliferative Diabetic RetinopathySession: Results of Clinical Trials and Late Breaking Session (Session 6)Presentation Date/Time: Friday, September 20, 12:35 PM – 12:40 PMPresenter: Veeral S. Sheth, MD, MBA, FACS, FASRS
  • Audio Presentation: US Phase 1 Clinical Trial of Sustained-Release Axitinib Hydrogel Implant (AXPAXLI) in Subjects with Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy DataDate/Time: Available on terminals throughout the meetingPresenter: Jordan M. Graff, MD, FACS

About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

1 Year Ocular Therapeutix Chart

1 Year Ocular Therapeutix Chart

1 Month Ocular Therapeutix Chart

1 Month Ocular Therapeutix Chart

Your Recent History